Stroke in atrial fibrillation: epidemiology and thromboprophylaxis

G Y H Lip1

  • 1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk

Insights

Atrial fibrillation (AF) stroke risk can be reduced with oral anticoagulation (OAC). New OACs and improved risk assessments aim to optimize thromboprophylaxis and prevent AF-related strokes.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a common heart rhythm disorder linked to significant stroke and thromboembolism risks.
  • Oral anticoagulation (OAC) effectively prevents AF-related stroke, yet its use remains suboptimal due to limitations of current vitamin K antagonist (VKA) therapies.
  • Newer OAC agents offer advantages over VKAs, presenting an opportunity to improve thromboprophylaxis and reduce stroke incidence.

Purpose of the Study:

  • To provide a comprehensive overview of stroke in AF, focusing on clinical epidemiology.
  • To review current stroke and bleeding risk assessment strategies for AF patients.
  • To examine the current provision and future directions of thromboprophylaxis in AF management.

Main Methods:

  • Literature review of epidemiological data and clinical trial evidence on AF and stroke.
  • Analysis of current guidelines and clinical practices for OAC and thromboprophylaxis.
  • Evaluation of emerging OAC agents and risk stratification tools.

Main Results:

  • AF is a major cause of stroke, but effective prevention is achievable with OAC.
  • Suboptimal thromboprophylaxis is partly due to VKA limitations; newer OACs show promise.
  • Enhanced stroke and bleeding risk assessments are crucial for personalized OAC decisions.

Conclusions:

  • Optimizing OAC use in AF, aided by novel agents and refined risk assessment, is key to reducing stroke burden.
  • Improved risk stratification can identify patients who truly need anticoagulation and those who do not.
  • The review highlights the need for better clinical decision-making tools for AF thromboprophylaxis.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.